Health News  Health Library  Health Topics  Healthy Living  My Health Manager Today's Headlines  Health Alerts  Health News Feature Future of Medicine  Health Observances  Product Recalls Illnesses & Conditions  Drug Guide  FDADrug Approvals  Medical Tests Self-Help Resources  Complementary Medicine  Medline Search Allergies   Asthma   Back Pain  Cancer  Caregiver  Diabetes  Digestive Disorders  Heart Disease Kidney Disease  Men's Health  Mental Health  Orthopedic Health  Parenting  Patient Safety Pregnancy  Senior's Health  Stress  Stroke  Weight Management  Women's Health Fitness  Nutrition  Mind & Body  Family & Home Sign Me Up!  Returning User Login  Privacy Policy

Health News Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.
FDA Approves Avastin for Most Common Kidney Cancer In combination with a second drug
TUESDAY, Aug. 4 (HealthDay News) -- The drug Avastin has been approved in the United States for treating people with metastatic renal cell carcinoma, the most common form of kidney cancer. The U.S. Food and Drug Administration approved Avastin to be used in combination with the drug interferon-alpha, Agence France Presse reported. A study found that people treated with a combination of the drugs lived nearly twice as long without disease progression compared to people treated with only interferon-alpha. Since the end of 2007, Avastin has been available in Europe as a first-line treatment for advanced kidney cancer, AFP reported. Last week, European officials approved the drug for treatment of breast cancer. More information The FDA has more about this drug's history.
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Health News Provided By: